Stay updated with breaking news from Patrickj Haley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among […]
Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $28.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 27.85% from the stock’s previous close. […]
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.46, but opened at $21.64. Exelixis shares last traded at $21.17, with a volume of 911,024 shares trading hands. The biotechnology company reported $0.12 […]
Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The company had revenue of $425.23 million during the quarter, compared to analysts’ expectations of $461.04 million. Exelixis had a return on equity […]
Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The company had revenue of $425.23 million during the quarter, compared to analysts’ expectations of $461.04 million. Exelixis had a return on equity […]